
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics is a promising bio-pharmaceutical company with strong potential in its late-stage product VIZZ. With continuously increasing revenues and a strong track record of cumulative pack sales, the company is on track for growth. With its recent expansion into international markets and a strong product profile, LENZ has the potential for even further success and market penetration. Though risks exist, the company has shown good management and financial control, making it a top pick for investors looking for growth in the biopharmaceutical sector.
Bears say
LENZ Therapeutics is facing a potential opportunity for success with their novel product, VIZZ, which has shown promising real-world efficacy and safety as compared to its competitor VUITY. However, there are concerns surrounding the commercial appeal of VIZZ due to its potential manufacturing and financial limitations. Additionally, further data and analysis is needed to fully validate the success of VIZZ in the market, which could potentially impact the company's financials and overall success.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares